SABCS 2025: Key Takeaways Reshaping Breast Cancer Treatment
The San antonio Breast Cancer Symposium (SABCS) 2025, held December 9-12 in San Antonio, Texas, delivered a wealth of groundbreaking data poised to redefine breast cancer treatment across all subtypes.The meeting brought together leading clinicians, researchers, and oncology pharmacists, focusing on advancements in targeted therapies, optimized treatment sequencing, crucial safety considerations, and the expanding, vital role of pharmacists in the era of precision oncology. Here’s a breakdown of the most impactful findings from SABCS 2025:
[Image of San Antonio Riverwalk | Image Credit: © Liang – stock.adobe.com – positioned right, cropped for visual appeal]
1.Ribociclib Continues to Solidify its Place in HR+/HER2- Breast Cancer
Long-term follow-up data from the pivotal MONALEESA trials further cemented ribociclib (Kisqali; Novartis) as a cornerstone of treatment for hormone receptor-positive (HR+), HER2-negative advanced breast cancer. Updated results showcased sustained progression-free survival (PFS) benefits and a manageable safety profile, reinforcing its integral role when combined with standard endocrine therapy. These findings provide clinicians



![Tetanus Vaccine India: Schedule, Types & Side Effects [2024 Update] Tetanus Vaccine India: Schedule, Types & Side Effects [2024 Update]](https://i0.wp.com/medifyhome.com/wp-content/uploads/2025/12/ne.jpeg?resize=330%2C220)



![Tetanus Vaccine India: Schedule, Types & Side Effects [2024 Update] Tetanus Vaccine India: Schedule, Types & Side Effects [2024 Update]](https://i0.wp.com/medifyhome.com/wp-content/uploads/2025/12/ne.jpeg?resize=150%2C100)

